retatrutide clinical trial results 2024 2025 retatrutide weight loss study Before and After: Doctor Reveals Real New Obesity Drug Helped People

Research Insights Superior Weight Loss Outcomes In a 48-week phase 2 study, adults with obesity treated with retatrutide experienced mean weight reductions of 22.8% (8 mg dose) and 24.2% (12 mg dose), outperforming other weight loss medications

Please reach out with any questions PRIOR to completing our intake forms

The compound, called Vykat XR, was developed by Soleno Therapeutics

No se aceptan todos los planes de seguro

What clinical trial data supports these weight loss numbers

This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited